Good day. Lots of mood swings in the board, to sa
Post# of 148282
(Total Views: 750)
Posted On: 05/02/2020 8:35:44 AM
Good day. Lots of mood swings in the board, to say the least, we have become more of “day traders” than long-term investors and the optimism becomes pessimism very rapidly depending on the hour of the day 
We submitted the BLA and will have revenue soon. This is critical and should be very happy about it. Many of us invested simply because of this and we are almost there. NP is already having meetings with Vyera and getting ready for launch. This alone should put the SP way above of what it is today.
There have been lots of discussions about the fairness of the FDA, please don’t ask me about it
but Nader’s love affair with it is simply an expression of the Stockholm syndrome. He is just fighting for survival and can’t say anything negative, and, practically, I think is the best venue for all of us.
The FDA being fair or not will not matter at the end. The importance of the publications that will come cannot be understated. Dr. Paterson will try and explain to the world what is COVID from the clinical perspective (how the illness operates from the immunoscience approach).
This will be backed up with measurements of IL-6, RANTES and CD4/CD8 at days 0, 3 and 7 and clinical results of 11 patients from Montefiori (first paper).
So, he will announce: “the illness is inside here and Leronlimab is the key to go in”. Few companies have CCR5 antagonists if indeed RANTES is the problem induced by COVID (small if given Dr. Patterson’s decades of experience on the subject).
The medical community and the scientific press will have to accept the facts. NIH and FDA will follow. Will Dr. Fauci accept us right away ??? No, he will have to be dragged to it as CYDY does not have 9 people in COVID-19 treatment guidelines panel, and FDA will not change the rules for us midway so we can get a certain and quick SOC denomination.
But we will succeed because we have FACTS, DATA and demonstrable clinical outcomes.
Once the paper(s) are published a different tone will be heard. The prompt approval of Remdesivir with the weak data they have smells of desperation (we all are), and other factors that should not be discussed here. Let’s use this in our favor.
Our task, once the paper is published, is to scatter it to the four winds. I am preparing a list of journalists and doctors and a “cover” letter to start sending once the publication is available. I suggest you all do the same.
We were talking about turning points few days back. Imo BLA was one (HIV) and the papers will be the turning point of COVID.
We submitted the BLA and will have revenue soon. This is critical and should be very happy about it. Many of us invested simply because of this and we are almost there. NP is already having meetings with Vyera and getting ready for launch. This alone should put the SP way above of what it is today.
There have been lots of discussions about the fairness of the FDA, please don’t ask me about it
but Nader’s love affair with it is simply an expression of the Stockholm syndrome. He is just fighting for survival and can’t say anything negative, and, practically, I think is the best venue for all of us. The FDA being fair or not will not matter at the end. The importance of the publications that will come cannot be understated. Dr. Paterson will try and explain to the world what is COVID from the clinical perspective (how the illness operates from the immunoscience approach).
Quote:
“COVID-19 is a RANTES condition”
This will be backed up with measurements of IL-6, RANTES and CD4/CD8 at days 0, 3 and 7 and clinical results of 11 patients from Montefiori (first paper).
So, he will announce: “the illness is inside here and Leronlimab is the key to go in”. Few companies have CCR5 antagonists if indeed RANTES is the problem induced by COVID (small if given Dr. Patterson’s decades of experience on the subject).
The medical community and the scientific press will have to accept the facts. NIH and FDA will follow. Will Dr. Fauci accept us right away ??? No, he will have to be dragged to it as CYDY does not have 9 people in COVID-19 treatment guidelines panel, and FDA will not change the rules for us midway so we can get a certain and quick SOC denomination.
But we will succeed because we have FACTS, DATA and demonstrable clinical outcomes.
Once the paper(s) are published a different tone will be heard. The prompt approval of Remdesivir with the weak data they have smells of desperation (we all are), and other factors that should not be discussed here. Let’s use this in our favor.
Our task, once the paper is published, is to scatter it to the four winds. I am preparing a list of journalists and doctors and a “cover” letter to start sending once the publication is available. I suggest you all do the same.
We were talking about turning points few days back. Imo BLA was one (HIV) and the papers will be the turning point of COVID.
(18)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼